Arrow Research search

Author name cluster

Jiaru Wang

Possible papers associated with this exact author name in Arrow. This page groups case-insensitive exact name matches and is not a full identity disambiguation profile.

2 papers
1 author row

Possible papers

2

TCS Journal 2021 Journal Article

The t/s-diagnosability and t/s-diagnosis algorithm of folded hypercube under the PMC/MM* model

  • Yuhang Lin
  • Limei Lin
  • Yanze Huang
  • Jiaru Wang

A t / s -diagnosable system refers to such a system that all the faulty nodes of the system can be isolated within a set of size at most s in the presence of at most t faulty nodes. Moreover, it increases the allowed faulty nodes, hence enhancing the diagnosability of the system. We can find that the t / s -diagnosability of n-dimensional folded hypercube F Q n has not been studied under the PMC model and MM* model. In this paper, we determine the t / s -diagnosability of F Q n under the PMC model and MM* model. First, we propose some new fault tolerant properties of F Q n. Then we prove that the t / s -diagnosability of n-dimensional folded hypercube F Q n is ( n + 1 ) g − 1 2 ( g − 1 ) ( g + 2 ) for 2 ≤ g ≤ 1 2 ( n − 1 ) where s = ( n + 1 ) g − 1 2 ( g − 1 ) ( g + 2 ) + g − 2 under both the PMC model and MM* model. In addition, we establish two t / s -diagnosis algorithms of complexity O ( N l o g 2 N ) and complexity O ( N ( l o g 2 N ) 2 ) to isolate the faulty nodes in a node subset of the system under the PMC model and MM* model, respectively. The comparison analysis results showed that the t / s -diagnosability of F Q n is the largest, and it increases faster than the other types of diagnosability as n increases.

YNICL Journal 2018 Journal Article

Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas

  • Ziren Kong
  • Chengrui Yan
  • Ruizhe Zhu
  • Jiaru Wang
  • Yaning Wang
  • Yu Wang
  • Renzhi Wang
  • Feng Feng

Antiangiogenic therapy is a universal approach to the treatment of malignant gliomas but fails to prolong the overall survival of newly diagnosed or recurrent glioblastoma patients. Imaging biomarkers are quantitative imaging parameters capable of objectively describing biological processes, pathological changes and treatment responses in some situations and have been utilized for outcome predictions of malignant gliomas in anti-angiogenic therapy. Advanced magnetic resonance imaging techniques (including perfusion-weighted imaging and diffusion-weighted imaging), positron emission computed tomography and magnetic resonance spectroscopy are imaging techniques that can be used to acquire imaging biomarkers, including the relative cerebral blood volume (rCBV), Ktrans, and the apparent diffusion coefficient (ADC). Imaging indicators for a better prognosis when treating malignant gliomas with antiangiogenic therapy include the following: a lower pre- or post-treatment rCBV, less change in rCBV during treatment, a lower pre-treatment Ktrans, a higher vascular normalization index during treatment, less change in arterio-venous overlap during treatment, lower pre-treatment ADC values for the lower peak, smaller ADC volume changes during treatment, and metabolic changes in glucose and phenylalanine. The investigation and utilization of these imaging markers may confront challenges, but may also promote further development of anti-angiogenic therapy. Despite considerable evidence, future prospective studies are critically needed to consolidate the current data and identify novel biomarkers.